Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysosomal acid alpha-glucosidase (GAA) is a lysosomal enzyme that catalyzes the hydrolysis of α(1→4)-linked glucose residues from glycogen, producing free glucose within lysosomes. It is essential for normal cellular energy metabolism. Deficiency of GAA leads to Pompe disease, characterized by glycogen accumulation in lysosomes. Recombinant human GAA (rhGAA) is used for enzyme replacement therapy. High-resolution crystal structures are available for rhGAA, providing insights into its function and informing drug design.
Enzyme replacement therapy (ERT)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysosomal acid alpha-glucosidase (GAA).